8-K

 1

                        SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT



Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2003

                         Immunotechnology Corporation
             (Exact name of registrant as specified in its charter)

                                  Delaware
         (State or other jurisdiction of incorporation or organization)

                                 000-24641
                          (Commission File Number)

                               84-1016435
                     (I.R.S. Employer Identification No.)

        1661 Lakeview Circle, Ogden, Utah              84403
    (Address of principal executive offices)         (Zip Code)

Registrant's telephone number, including area code: (801)399-3632



                 (Former name, if changed since last report)

__________________________________
         (Former name or former address, if changed since last report)

______________
          (Registrant's Former Telephone Number, Including Area Code)




 2

          Item 5. Other Events and Regulation FD Disclosure.

Reference is made to our press release dated May 20, 2003.

Forward Stock Split.  On May 13, 2002, our Board of Directors approved a 5 for
1 stock split of the Registrant's issued and outstanding common stock in the
form of a dividend. The dividend will be payable on May 27, 2003 for
shareholders of record on May 23, 2003.  As a result of the 5:1 forward split,
the Registrant's total issued and outstanding stock will increase from
10,000,000 shares issued and outstanding to 50,000,000 shares issued and
outstanding.

The purpose for the stock split is to increase the marketability and liquidity
of the common stock and increase the number of issued and outstanding shares
of our common stock. As a result of the stock split, each share of the
Registrant's issued and outstanding common stock may be exchanged for 5 fully
paid and nonassessable shares of common stock, $0.001 par value per share.
Fractional shares will be rounded upward.

Change of Symbol and CUSIP Number.  Concurrent with the forward split, we also
intend to change our trading symbol and CUSIP Number. Therefore, our CUSIP
Number will be changed from 45253M 20 9 and our symbol will change from IMNT.
We will announce the new CUSIP Number and trading symbol when they become
available.

Effect on Merger Agreement between Registrant and Ultimate Security Systems
Corporation.  On April 21, 2003, we entered into an Agreement and Plan of
Merger with Ultimate Security Systems Corporation ("Ultimate"), a copy of
which was attached as an exhibit to our Form 8-K filed with the Securities and
Exchange Commission on April 23, 2003 (the "Merger Agreement"). The following
discussion regarding the terms of the Merger Agreement is subject to, and
qualified in its entirety by, the detailed provisions of the Merger Agreement
and any exhibits thereto.

The Merger Agreement provides that approximately 34,687,924 shares of Ultimate
securities held by the Ultimate Shareholders will be exchanged for shares of
our Common Stock on a one for one basis.  As a condition to the Merger
Agreement, Ultimate Shareholders holding Series A and B Preferred Shares must
convert such Preferred Shares to Ultimate common stock prior to the effective
date of the Merger.  Ultimate Preferred Shares are also entitled to accrued
and unpaid dividends totaling approximately $355,000 through March 31, 2003
which must also be converted to rights to receive common shares in the Merger
at a ratio of 1 share for each dollar owed.  The approximate number of shares
to be issued by us to the Ultimate shareholders assumes the conversion of all
Ultimate Preferred Shares and dividends.  Finally, as a condition to the
Merger Agreement, Ultimate Shareholders holding warrants for the purchase of
up to approximately 11,020,183 additional shares at an exercise price of $.50
per share (7,601,854) and $1.00 per share (3,418,329), exercisable until one
year following the effective date of the Merger, must also agree to convert
such warrants to a like number of warrants for the purchase of our Common
Stock on the same terms as their existing warrants.

Originally, approximately 34,687,924 shares of our Common Stock would be
issued to the Ultimate Shareholders in exchange for the shares of Ultimate
Common and Preferred Stock which would have resulted in approximately
44,687,924 Common Stock shares issued and outstanding.  In addition, assuming
the Ultimate warrant holders agree to convert their outstanding warrants, we
would have had warrants for the purchase of up to approximately 11,020,183


 3

additional shares at an exercise price of $.50 per share (7,601,854 warrants)
and $1.00 per share (3,418,329 warrants), exercisable until one year following
the effective date of the Merger.  We also contemplated issuing warrants for
the purchase of an additional 400,000 shares at $.10 per share, exercisable
for one year following the effective date of the Merger to Troika Capital
Investment, an entity whose principal is Mark Scharmann, our president.

We will also assume certain obligations related to Ultimate's existing
consulting and advisory service agreements with  Shulman & Associates and
Stenton Leigh Business Resources, Inc.  These agreements call for the issuance
of an aggregate of 4,000,000 options for the purchase of common stock at an
exercise price of $0.10 per share, subject to certain conditions, including
minimum financing being obtained following the effectiveness of the Merger
Agreement.

With the forward split of our stock, we will be required to prepare an
amendment to the Merger Agreement which provides that the aforementioned
issuances will be increased by a multiple of five (5). Therefore, we will
issue approximately 173,439,620 shares of our Common Stock to the Ultimate
Shareholders in exchange for the shares of Ultimate Common and Preferred Stock
which will result in approximately 223,439,620 Common Stock shares issued and
outstanding after the consummation of the Merger.  In addition, assuming the
Ultimate warrant holders agree to convert their outstanding warrants, we will
issue warrants for the purchase of up to approximately 55,100,915 additional
shares at an exercise price of $.50 per share (38,009,270 warrants) and $1.00
per share (17,091,645 warrants), exercisable until one year following the
effective date of the Merger.  We will also issue warrants for the purchase of
an additional 400,000 shares at $.10 per share, exercisable for one year
following the effective date of the Merger to Troika Capital Investment, an
entity whose principal is Mark Scharmann, our president.

We will also assume certain obligations related to Ultimate's existing
consulting and advisory service agreements with  Shulman & Associates and
Stenton Leigh Business Resources, Inc.  These agreements call for the issuance
of an aggregate of 4,000,000 options for the purchase of common stock at an
exercise price of $0.10 per share, subject to certain conditions, including
minimum financing being obtained following the effectiveness of the Merger
Agreement.

In order to have sufficient authorized capital to be able to reserve enough
shares for the warrants and options outstanding following the effectiveness of
the Merger, and to provide additional shares to be available for sale in
connection with Ultimate's proposed fund raising following the Merger, we will
also increase our capitalization from 50,000,000 authorized common shares to
500,000,000 shares of common stock.

Index to Exhibits

99.1      Press Release dated May 20, 2003

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Immunotechnology Corporation


May 19, 2003   By: /S/ Mark A. Scharmann
                       Mark A. Scharmann, President

EX-99

 1

Exhibit 99.1 Press Release

News
For Immediate Release

Ultimate Security Systems Corporation and ImmunoTechnology Corporation
Announce Plan to Split Stock

IRVINE, Calif., May 20, 2003 - Ultimate Security Systems Corporation (USSC) of
Irvine, Calif., manufacturer of the Power Lock(tm) vehicle security system and
ImmunoTechnology Corp. (OCT:BB:IMNT), have announced the intent to implement a
5 to 1 stock split of IMNT outstanding common stock.  The effective date will
be May 27, 2003.

The company's common stock will trade under the temporary ticker symbol of
IMNT, after which the company expects the symbol to change.  Further details
are disclosed in the company's Form 8-K.

Ultimate Security Systems Corporation (USSC) of Irvine, Calif., manufacturer
of the Power Lock(tm) vehicle security system and ImmunoTechnology Corp.
(OCT:BB:IMNT), have recently signed a definitive merger agreement. Completion
of the merger is imminent pending the approval of a S4 registration statement
to be filed with the SEC.  The new entity will retain the name USSC.  USSC CEO
James Cooper will remain at the helm.

Ultimate Security Systems Corporation (USSC) of Irvine, Calif. developed and
patented Power Lock, the only solid-state vehicle security system that is
guaranteed to prevent any vehicle from being hot-wired and driven away.  The
product attaches permanently to a vehicle's starter motor and cannot be
circumvented by cutting and jumping ignition wires, the "hot-wiring" technique
used by professional car thieves in the vast majority of stolen car cases
nationwide.

For additional information about Power Lock, contact the corporate
headquarters:  Ultimate Security Systems Corporation, 18271 West McDurmott,
Suite F Irvine, CA 92614 (800) 689-8004 or visit www.Powerlock.com

Media Contact:  Emily Curci, Hilary Kaye Associates (714) 426-0444;
ecurci@hkamarcom.com

Safe Harbor statement under the Private Securities Litigation Reform Act of
1995:  This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21B of the Securities
Exchange Act of 1934.  Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not statements of
historical fact and may be forward-looking statements.  Forward-looking
statements are based on expectations, estimates and projections at the time
the statements are made that involve a number of risks and uncertainties which
could cause actual results or events to differ materially from those presently
anticipated.  In particular, information in this release relates to the terms
of a merger transaction which is contingent on shareholder approval and the
effectiveness of a registration statement on Form S-4 to be filed with the
SEC.